| HIV Infections

Reyataz vs Stribild

Side-by-side clinical, coverage, and cost comparison for hiv infections.

Deep comparison between: Reyataz vs Stribild with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsStribild has a higher rate of injection site reactions vs Reyataz based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Stribild but not Reyataz, including UnitedHealthcare

Category

Reyataz

Stribild

At A Glance

RouteOral

FrequencyOnce daily

ClassHIV-1 protease inhibitor

RouteOral

FrequencyOnce daily

ClassIntegrase inhibitor + CYP3A inhibitor + nucleoside/nucleotide analog reverse transcriptase inhibitors

Indications

HIV Infections

HIV Infections

Dosing

HIV Infections (treatment-naive adults) 300 mg once daily with ritonavir 100 mg once daily with food, or 400 mg once daily with food if unable to tolerate ritonavir

HIV Infections (treatment-experienced adults) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily if taken with both tenofovir DF and H2-receptor antagonist

HIV Infections (pediatric patients 6 to less than 18 years, 15 to less than 35 kg) 200 mg once daily with ritonavir 100 mg once daily with food

HIV Infections (pediatric patients at least 35 kg) 300 mg once daily with ritonavir 100 mg once daily with food

HIV Infections (pediatric patients at least 3 months, 5 to less than 15 kg) 200 mg oral powder once daily with ritonavir 80 mg once daily with food

HIV Infections (pregnant patients) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily during second or third trimester when coadministered with either H2-receptor antagonist or tenofovir DF

HIV Infections One tablet (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg) taken orally once daily with food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance >=70 mL/min.

Contraindications

Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance where elevated plasma concentrations are associated with serious or life-threatening events (alfuzosin, cisapride, pimozide, orally administered midazolam, triazolam, ergot derivatives, lovastatin, simvastatin, lomitapide, sildenafil for pulmonary arterial hypertension, indinavir, irinotecan, lurasidone when boosted with ritonavir, apalutamide, encorafenib, ivosidenib, elbasvir/grazoprevir, glecaprevir/pibrentasvir)
Coadministration with strong CYP3A inducers (rifampin, St. John's wort, carbamazepine, phenobarbital, phenytoin, nevirapine)

Coadministration with alfuzosin
Coadministration with carbamazepine, phenobarbital, or phenytoin
Coadministration with rifampin
Coadministration with lurasidone or pimozide
Coadministration with dihydroergotamine, ergotamine, or methylergonovine
Coadministration with St. John's wort (Hypericum perforatum)
Coadministration with lomitapide, lovastatin, or simvastatin
Coadministration with sildenafil when used for pulmonary arterial hypertension
Coadministration with triazolam or orally administered midazolam

Drug Interactions

1374View drug interactions

3640View drug interactions

Adverse Reactions

Most common (>=2%) Nausea, jaundice/scleral icterus, rash, headache, insomnia, dizziness, vomiting, abdominal pain, diarrhea, fever, myalgia, depression, peripheral neurologic symptoms

Serious Cardiac conduction abnormalities (PR interval prolongation, second-degree AV block, third-degree AV block), chronic kidney disease, nephrolithiasis, cholelithiasis

Postmarketing Edema, QTc prolongation, left bundle branch block, pancreatitis, hepatic function abnormalities, cholecystitis, cholestasis, diabetes mellitus, hyperglycemia, arthralgia, interstitial nephritis, granulomatous interstitial nephritis, alopecia, maculopapular rash, pruritus, angioedema

Most common (>=5%) Diarrhea, nausea, headache, fatigue

Serious Severe acute exacerbations of hepatitis B in coinfected patients, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, bone loss and mineralization defects, immune reconstitution syndrome

Postmarketing Allergic reactions including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, increased amylase, abdominal pain, hepatic steatosis, hepatitis, increased liver enzymes, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria, asthenia

Pharmacology

Atazanavir is an azapeptide HIV-1 protease inhibitor that selectively inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1-infected cells, preventing formation of mature virions.

STRIBILD is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor), cobicistat (a CYP3A inhibitor that boosts elvitegravir levels), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Reyataz